non-Hodgkin lymphoma | pharmaphorum

Skip to main content

Saturday 23 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

non-Hodgkin lymphoma

News

Gilead Sciences

Gilead expands CAR-T deal with MaxCyte, Precision files for ...

It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-sh

News

NICE1

Adcetris cleared by NICE in aggressive blood cancer

NICE has recommended regular NHS funding for Takeda’s Adcetris in an aggressive type of non-Hodgkin lymphoma after the company submitted further data to support its case.

News

kitepharma

Kite and Fosun appoint leader for CAR-T debut in China

But rival Juno finally gives up on lead therapy.

News

Imbruvica

J&J/AbbVie blood cancer drug gets fifth US indication

Imbruvica approved in marginal zone lymphoma.

News

Cancer-cell

Juno boosted by CAR-T trial findings in NHL

Biotech plans pivotal trial next year.

Editor's Picks

Trump pick of RFK for top US health job astounds critics News

23andMe ends drug development and slashes staff

BioNTech buys Biotheus and its Keytruda rival for $950m

Chasing $80bn sales target, AZ unveils $3.5bn US investment News

London "is number one European city in life sciences"

News

Stop sign

Neurogene drops high-dose arm in Rett study after death

The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died

Sales & Marketing

Happy lady reading from tablet

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company